Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative colitis (UC), whereas tumor necrosis factor-alpha (TNF-α) inhibitors are primarily reserved for moderate to severe disease that is refractory to conventional therapies or for the first-line treatment of very severe disease. Takeda’s cell adhesion molecule (CAM) inhibitor, Entyvio; Janssen’s IL-12 / IL-23 inhibitor, Stelara; and Pfizer’s JAK inhibitor, Xeljanz / Xeljanz XR are alternative options, especially for TNF-α-refractory patients. These three newer drugs are not approved for pediatric UC, but, given the limited number of therapies available for pediatric patients who fail TNF-α inhibitors, physicians may turn to them as last-line options.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Markets covered: United States
Key companies: AbbVie, Janssen, Pfizer, Salix, Takeda
Key drugs: Apriso, Entyvio, Humira, Pentasa, Remicade, Stelara, Xeljanz